Clin Res Cardiol (2021) DOI DOI https://doi.org/10.1007/s00392-021-01843-w |
||
Targeting PGE2 to treat sepsis-induced acute heart failure | ||
R. Schell1, B. Niehaus2, C. Achilles2, F. Alban2, C. Haslinger2, H. A. Katus1, N. Frey1, J. Backs2 | ||
1Klinik für Innere Med. III, Kardiologie, Angiologie u. Pneumologie, Universitätsklinikum Heidelberg, Heidelberg; 2Molekulare Kardiologie und Epigenetik, Universitätsklinikum Heidelberg, Heidelberg; | ||
Introduction: We recently unmasked a new link between inflammation and adverse cardiac remodeling via activation of the transcription factor myocyte enhancer factor 2 (MEF2). MEF2D mediates acute contractile dysfunction and is regulated by a signaling pathway consisting of PGE2, EP3-receptors, PKD and Rac1 leading to a nucleo-cytoplasmic shuttling of HDAC5 with subsequent activation of MEF2. On that account, we aimed to target inflammation induced acute heart failure by inhibition of PGE2 formation and EP-receptor activation in vivo.
BALB/c-wildtype-mice were pre-treated with the irreversible, unselective and widely used COX-inhibitor Acetylsalicylic acid (ASA, 100mg/kg bodyweight) one hour prior to induction of an inflammatory acute heart failure model. This E. coli derived lipopolysaccharide (LPS) induced endotoxemia leads to an acute severe depression of left-ventricular function, which was markedly abolished by ASA-pretreatment (LVEF after 24 hours in the LPS-treated groups: 50% in contrast to 22% in sham-treated littermates). ASA-pretreatment almost completely diminished myocardial PGE2-levels and attenuated LPS-induced overexpression of typical target genes of MEF2 (e.g. Nur77), confirming that PGE2-driven activation of the described signaling pathway leads to reduced MEF2 activation and consecutively improved outcome in terms of left ventricular function.
|
||
https://dgk.org/kongress_programme/jt2021/aP614.html |